目的探讨甲氨蝶呤联合来氟米特治疗类风湿关节炎(RA)患者的临床疗效。方法将80例RA患者随机分为两组,治疗组采用甲氨蝶呤联合来氟米特进行治疗,对照组采用甲氨蝶呤联合羟氯喹进行治疗;观察疗效和治疗前及治疗后1、2、3、4月的抗环瓜氨酸肽抗体(ACCP)、C反应蛋白(CRP)和类风湿因子(RF)的变化。结果治疗2月后,两组之间的总有效率差异有统计学意义(P<0.05);治疗2、3、4个月时,治疗组的的ACCP、CRP和RF均明显低于对照组(P<0.05)。结论甲氨蝶呤与来氟米特联合用药能有效地治疗RA,对RA患者的ACCP、CRP和RF水平降低程度显著,有效控制病情,为临床治疗RA提供依据。 Objective To investigate the clinical efficacy of methotrexate combined with leflunomide in patients with rheumatoid arthritis (RA). Methods Eighty RA patients were randomly divided into two groups. The treatment group was treated with methotrexate combined with leflunomide, while the control group was treated with methotrexate combined with hydroxychloroquine. The therapeutic effects were observed before and after treatment, Anti-cyclic citrullinated peptide antibody (ACCP), C-reactive protein (CRP) and rheumatoid factor (RF) changes in February, March and April. Results After 2 months of treatment, the total effective rate was significantly different between the two groups (P <0.05). At the 2nd, 3rd, 4th month, the ACCP, CRP and RF of the treatment group were significantly lower than those of the control group (P <0.05). Conclusion Combination therapy with methotrexate and leflunomide can effectively treat RA and significantly reduce the levels of ACCP, CRP and RF in RA patients, effectively controlling the disease and providing the basis for clinical treatment of RA.